Aker BioMarine, a global biotech innovator and world-leading supplier of krill, announces two new talents on the Human Nutrition team. Katina Handeland, PhD., and Yunpeng Ding, PhD. have both joined Aker BioMarine as Directors for Research & Development (R&D). They will be responsible for research within the company’s human health and nutrition department.
“We are thrilled to add such top caliber scientists to our Human Health and Nutrition team,” says Tim de Haas, EVP for Human Nutrition at Aker BioMarine. “Each of them brings extensive knowledge and experience to the table, elevating our current research efforts as well as new areas for the future.”
Handeland will be working to both design and follow-up the pre-clinical and clinical trials for the human health portfolio, studying the biological effects of krill and its benefits.
“I am very excited to join the team and to play a part in contributing to better and healthier lives globally,” says Katina Handeland. “In addition to the work currently in progress, I will help support the establishment of potential new product lines and areas of focus.”
Katina Handeland holds a Ph.D. in Nutrition from the University of Bergen. She has extensive experience with innovation projects for medical nutrition, and she currently serves as the President of the Board for the Norwegian Nutrition Society.
Yunpeng Ding holds a Ph.D. in Epidemiology and Biostatistics from the University of Bergen. He has previously worked with drug development and early phase clinical trials, and he has most recently served as a senior statistician for a medical research company in Norway.
“My focus will be on Superba Krill oil and its potential for sports performance, metabolic syndrome, as well as cardiovascular and cognitive health,” says Ding. “Going forward, I foresee adding healthy aging and personalized nutrition to my research, as we expand our efforts to find sustainable solutions to improve public health.”
Handeland and Ding are based at the company headquarters in Lysaker, Norway.
About Aker BioMarine ASA
Aker BioMarine is a biotech innovator and Antarctic krill-harvesting company, dedicated to improving human and planetary health. Listed on Oslo Stock Exchange, the company develops krill-based ingredients for pharmaceutical, nutraceutical (Superba®), aquaculture (QRILL® Aqua), and animal feed applications (QRILL® Pet), including INVI™, a highly concentrated protein isolate, and LYSOVETA™, a targeted transporter of EPA and DHA from krill. Aker BioMarine’s fully transparent value chain stretches from sustainable krill harvesting in pristine Antarctic waters through its Montevideo logistics hub, Houston production plant, and to customers around the world. The company’s strong focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste. Read more: www.akerbiomarine.com